North Carolina State University

HOUSTON, Oct. 31, 2024 /PRNewswire/ -- Geneial, a company advancing private, community-led genetic medicine, has been awarded a one-year pilot project through National Heart, Lung, and Blood Institute's BioData Catalyst® (BDC) program and the Renaissance Computing Institute (RENCI) to advance AI tools to streamline the complex process of transforming biomedical data into analysis-ready formats. Geneial will collaborate with RENCI, NHLBI BioData Catalyst (BDC), and performers from the Advanced Research Projects Agency for Health (ARPA-H) Biomedical Data Fabric (BDF) Toolbox program to unlock new possibilities for precision medicine research and implementation on a broad scale. Continue Reading As healthcare research relies increasingly on mapping fragmented datasets to standardized and interoperable data models, Geneial's new AI tools will optimize and automate this process, which currently requires extensive manual effort and significant financial investment. Geneial's technology will offer flexible, efficient conversion to current standards—such as the Global Alliance for Genomics and Health (GA4GH) Phenopackets format—while anticipating future data needs and supporting adaptable, evolving standards. Geneial expands into generative AI space to simplify biomedical data management, reducing costs and improving access. Post this "Data standardization remains a significant challenge in precision medicine," said Dr. Adam Hansen, CEO of Geneial. "Our collaboration with ARPA-H, NHLBI, and RENCI directly addresses this critical bottleneck, enabling researchers to focus on groundbreaking discoveries rather than laborious data management. By advancing tools that meet today's needs and adapt to tomorrow's, we're substantially reduce data wrangling costs as we enhance the utility of biomedical data." This work aligns with Geneial's broader vision of a global, privacy-preserving data exchange, one that allows individuals and data custodians to maintain control while connecting researchers, drug developers, and healthcare systems with harmonized, high-quality data. It marks a significant expansion of the business into AI-driven data standardization, while reinforcing Geneial's commitment to accelerating progress in genomic medicine, making it easier for researchers to derive insights that can lead to better, more inclusive healthcare. Expanding Expertise in AI and Healthcare Innovation In alignment with its growth strategy, Geneial has recently expanded its team with notable experts in AI and healthcare data. Joshua Proulx, formerly Chief Data Scientist at Safe & Reliable Healthcare (acquired by Vizient) and previously its Chief Technology Officer, brings extensive experience in healthcare data reliability and safety. Bryce Daines, Ph.D., formerly Chief Technology Officer at Modulus Therapeutics, brings deep expertise in high-throughput AI applications for biomedical research. Together, Proulx, Daines and other new team members strengthen Geneial's position as a forward-thinking partner in healthcare data innovation. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About RENCI RENCI (Renaissance Computing Institute) develops and deploys advanced technologies to enable research discoveries and practical innovations. RENCI partners with researchers, government, and industry to engage and solve the problems that affect North Carolina, our nation, and the world. An institute of the University of North Carolina at Chapel Hill, RENCI was launched in 2004 as a collaboration involving UNC Chapel Hill, Duke University, and North Carolina State University. About Geneial Geneial is committed to creating equitable health futures by building secure, human-centered solutions for biomedical data. As Geneial expands into AI-driven data standardization, it empowers data owners and researchers with tools that unlock the value of harmonized data, driving forward precision medicine and improving access to transformative insights. SOURCE Geneial WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and took place under a sponsored scientific research agreement with NC State University. The study measured tumor volumes in treated and untreated subjects over the course of the experiment. Tumor volume measurements in the treated group exhibited minimal changes, suggesting that the treatment effectively inhibited tumor growth. Additionally, all tumors in the treated animals displayed remarkable consistency in volume, with standard deviation error bars barely visible—a strong indication of the treatment's uniformity and reproducibility in suppressing tumor growth. "These early findings are incredibly encouraging and demonstrate that our treatment has the potential to halt tumor progression consistently across subjects," said Robb Knie, CEO of Hoth Therapeutics. "The stability and low variability observed in tumor volumes among treated animals are indicative of a promising therapeutic effect, and we're excited to move forward with further testing as we process additional tissue data." Key observations from the initial data include: Stabilized Tumor Growth: Tumor volumes in treated subjects remained remarkably stable over the course of the study, suggesting that the treatment may significantly inhibit tumor growth. Consistency Across Subjects: Tumor sizes were highly consistent across all treated animals, as demonstrated by the minimal error bars on the graph. This uniform response highlights the treatment's potential reproducibility and reliability. Comparison with Untreated Controls: In contrast, untreated subjects showed greater variability and an increase in tumor volume, underscoring the potential efficacy of the treatment in slowing or halting tumor growth. As Hoth Therapeutics advances this research, the company will continue analyzing additional tissue data to further validate these results. The company is committed to moving forward with the development of this promising treatment and exploring its full potential for patients in need of effective cancer therapies. For more information on Hoth Therapeutics' development programs, please visit . About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit . Forward-Looking Statement This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. Investor Contact: LR Advisors LLC Email: [email protected] Phone: (678) 570-6791 SOURCE Hoth Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DURHAM, N.C., Oct. 23, 2024 /PRNewswire/ -- EydisBio, an innovative pharmaceutical company dedicated to developing novel treatments for various autoimmune and inflammatory diseases, is excited to announce that it has been awarded a $0.5 million Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health's (NIH) National Institute on Aging (NIA). This grant will support EydisBio's pioneering research into new therapeutic approaches for Alzheimer's disease, focusing on the inhibition of TGFβ-activated protein kinase 1 (TAK1). The project will be conducted in collaboration with Dr. Jun Ninomiya-Tsuji and her team at North Carolina State University who are focusing on understanding the molecular mechanisms of TAK1 and its role in driving various inflammatory-diseases. For more information about EydisBio and their groundbreaking research, please visit . "We are deeply honored to receive this NIH grant and to collaborate with Dr. Jun Ninomiya-Tsuji and her distinguished team at North Carolina State University," said Dr. Tim Haystead, Founder and President of EydisBio. "This funding empowers us to investigate innovative approaches in Alzheimer's disease research, bringing us closer to developing effective treatments for this devastating condition. Together, we are dedicated to making a meaningful impact on the lives of patients and their families." Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, leading to memory loss, cognitive decline, and ultimately, loss of independence. Current treatments offer limited symptomatic relief, and there is a critical need for innovative therapies that can slow or halt disease progression. EydisBio's research focuses on targeting TAK1, a critical regulator of neuronal necrosis and neuroinflammation in Alzheimer's disease. Preliminary studies have shown that TAK1 signaling contributes to both neuroinflammatory and necroptotic pathways, which are key drivers of neuronal death in Alzheimer's disease. By inhibiting TAK1, EydisBio aims to reduce neuroinflammation and neuronal damage, offering a potential new strategy for treating the disease. Key findings from EydisBio's preclinical work include: Identification of TAK1 as a critical mediator: TAK1 regulates TNF and glutamate signaling in neurons, switching from inflammatory to necroptotic signaling, which contributes to neuronal death. Efficacy of TAK1 inhibition: Genetic and pharmacological inhibition of TAK1 has been shown to rescue neuronal loss in preclinical models of Alzheimer's disease. Development of selective TAK1 inhibitors: EydisBio has developed a series of TAK1 inhibitors with low nanomolar potency, selectivity within the human kinome, and oral bioavailability. These inhibitors have demonstrated significant promise in reducing neuroinflammation and neuronal necrosis in preclinical studies. The Phase I SBIR grant will fund further preclinical studies to validate these findings and identify lead compounds for future development. This project aims to generate critical preclinical data on the viability of targeting the TAK1 pathway as a novel therapy for Alzheimer's disease. Media Contact: Robert Freeze, [email protected] SOURCE EydisBio, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED